MDT Earnings

MDT reported its earnings on 2026-02-17, showcasing a revenue of 9.02B against an estimate of 8.90B, resulting in a 1.31% surprise. The EPS was 1.36, surpassing the expected 1.33 by 2.26%. The stock experienced a -3.1% price change on the earnings day and a -2.64% change over the next five days, reflecting market reactions to the results.

Following MDT's earnings announcement on 2026-02-17, the stock price moved by -3.1% on the day of the release. Over the subsequent five days, it saw a -2.64% change. Historically, MDT's stock price tends to shift by an average of -1.26% in the 10 days leading up to earnings and 2.26% in the 10 days following, providing insight into potential market.

For 2026/Q4, analysts estimate MDT's annual revenue to reach 9.63B, while the EPS is projected at 1.69. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MDT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MDT's stock price typically moves by -1.26% in the 10 days before its earnings and 2.26% in the 10 days after. For the upcoming 2026/Q4 earnings, analysts expect an EPS of 1.69 and revenue of 9.63B.

Medtronic's earnings call reveals strong revenue growth, positive product developments, and optimistic guidance. The increase in full-year revenue growth guidance to 5.5% and the raised EPS guidance reflect confidence in future performance. The Q&A section supports this with plans for accelerated growth in key areas and high single-digit EPS growth. Despite some management vagueness, the overall sentiment is positive, with strong growth in the MedSurg and Diabetes businesses and strategic investments. The lack of market cap information limits the prediction accuracy, but the strong fundamentals suggest a positive stock price movement.